Cg Oncology (CGON) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
1.1M
Operating Income
-114.7M
-10,067.25%
Net Income
-88.0M
-7,729.50%
EPS (Diluted)
-$1.41
Balance Sheet Metrics
Total Assets
754.8M
Total Liabilities
21.4M
Shareholders Equity
733.4M
Debt to Equity
0.03
Cash Flow Metrics
Operating Cash Flow
-74.1M
Free Cash Flow
-78.9M
Revenue & Profitability Trend
Cg Oncology Income Statement From 2021 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 1.1M | 204.0K | 191.0K | 10.4M |
| Cost of Goods Sold | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 115.8M | 55.7M | 35.4M | 23.0M |
| Operating Income | -114.7M | -55.4M | -35.2M | -12.6M |
| Pre-tax Income | -88.0M | -48.6M | -35.4M | -12.8M |
| Income Tax | - | - | - | - |
| Net Income | -88.0M | -48.6M | -35.4M | -12.8M |
| EPS (Diluted) | -$1.41 | -$15.65 | -$11.71 | -$0.55 |
Income Statement Trend
Cg Oncology Balance Sheet From 2021 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | 754.2M | 194.1M | 147.2M | 58.4M |
| Non-Current Assets | 587.0K | 5.2M | 539.0K | 285.0K |
| Total Assets | 754.8M | 199.3M | 147.7M | 58.7M |
| Liabilities | ||||
| Current Liabilities | 21.4M | 14.3M | 15.4M | 6.0M |
| Non-Current Liabilities | 52.0K | 257.0K | 7.1M | 12.5M |
| Total Liabilities | 21.4M | 14.5M | 22.6M | 18.4M |
| Equity | ||||
| Total Shareholders Equity | 733.4M | 184.8M | 125.2M | 40.3M |
Balance Sheet Composition
Cg Oncology Cash Flow Statement From 2021 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | -88.0M | -48.6M | -35.4M | -12.8M |
| Operating Cash Flow | -74.1M | -44.2M | -34.2M | -10.8M |
| Investing Activities | ||||
| Capital Expenditures | -234.0K | 0 | -14.0K | -97.0K |
| Investing Cash Flow | -300.8M | -121.2M | -55.4M | -97.0K |
| Financing Activities | ||||
| Dividends Paid | - | - | - | - |
| Financing Cash Flow | 625.7M | 84.9M | 119.5M | 15.2M |
| Free Cash Flow | -78.9M | -45.7M | -29.8M | -13.8M |
Cash Flow Trend
Cg Oncology Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-19.18
Forward P/E
-14.58
Price to Book
2.81
Price to Sales
2,989.14
PEG Ratio
-14.58
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-81,161.54%
Return on Equity
-16.58%
Return on Assets
-12.85%
Financial Health
Current Ratio
30.97
Debt to Equity
0.15
Per Share Data
EPS (TTM)
-$1.50
Book Value per Share
$9.25
Revenue per Share
$0.01
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| cgon | 2.0B | -19.18 | 2.81 | -16.58% | 0.00% | 0.15 |
| Vertex | 124.2B | 32.82 | 7.53 | -5.64% | -8.91% | 10.00 |
| Regeneron | 59.1B | 13.92 | 1.97 | 15.96% | 31.94% | 9.20 |
| Belite Bio | 1.9B | -54.37 | 12.07 | -33.43% | 0.00% | 0.00 |
| Disc Medicine | 1.9B | 4.99 | 2.93 | -23.34% | 0.00% | 4.64 |
| Amicus Therapeutics | 1.9B | -35.67 | 9.87 | -18.12% | -5.41% | 229.11 |
Financial data is updated regularly. All figures are in the company's reporting currency.